PDS Biotechnology Corp — Director's Dealing 2015

Oct 1, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-09-30

Reporting Person: Yaman Alpaslan (Vice Pres., Tech. Op. & Manu.)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to purchase)	$8.28	2024-03-27	Common Stock (56282)		Direct
Stock Option (right to purchase)	$6.36	2025-03-11	Common Stock (21928)		Direct

Footnotes

F1: This option, representing a right to purchase a total of 56,282 shares of Common Stock, became exercisable on February 10, 2015, with 25% vesting on that date and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

F2: This option, representing a right to purchase a total of 21,928 shares of Common Stock, will become exercisable on March 11, 2016, with 25% vesting on that date and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.